Can a vaccine stop Antibiotic-Resistant gonorrhea?
NCT ID NCT07758972
First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time
Summary
This first-in-human trial tests an experimental vaccine called LTB-NG6, designed to protect against gonorrhea. The study will enroll healthy adults aged 18-50 to evaluate the vaccine's safety and its ability to trigger an immune response. Participants will receive either the vaccine at different doses or a placebo, and researchers will monitor for side effects and measure antibody levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LTB-NG6, an experimental vaccine against Neisseria gonorrhoeae
- What this could lead to
- If successful, this could lead to a vaccine that prevents gonorrhea, a common sexually transmitted infection with rising antibiotic resistance.
- What could go wrong
- This is an early-phase trial focused on safety and immune response, not effectiveness. The vaccine may not produce a strong enough immune response or may cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEISSERIA GONORRHEA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nuvisan GmbH
RECRUITINGNeu-Ulm, Bavaria, 89231, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.